DNA Methylation Status of HYAL1 in Malignant and Benign Thyroid Nodules
Hormone and Metabolic Research · 01.12.2023 · 55 (12) · 869-875
DOI: 10.1055/a-2188-0050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.12.2023. Verfasst von Mengxia Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Biomarkers, Thyroid Neoplasms, Thyroid Nodule. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Differentiation between benign and malignant thyroid nodules has been a challenge in clinical practice. Exploring a novel biomarker to determine the malignancy of thyroid nodules has important implications. We semi-quantitatively determined the DNA methylation levels of four CpG sites located at the gene body of HYAL1 in formalin-fixed paraffin-embedded (FFPE) tissue samples from 190 early-stage papillary thyroid cancer (PTC) cases and 190 age- and gender-matched subjects with benign thyroid nodule (BTN). HYAL1 expression was evaluated by immunohistochemical (IHC) staining in another cohort of 55 PTC and 55 matched BTN cases. Covariates-adjusted odds ratios (ORs) for 10% increased methylation were calculated by binary logistic regression. A 165 bp amplicon covering four CpG sites at the second exon of HYAL1 gene was designed. After adjusted for all covariates, higher methylation level of HYAL1_CpG_3,4 in the FFPE tissue was associated with PTC (OR per 10% increased methylation=1.53, p=0.025), even with stage І PTC (OR per 10% increased methylation=1.58, p=0.021). Hypermethylation of HYAL1_CpG_3,4 had a significant association with early-stage PTC in the females (OR per 10% increased methylation=1.60, p=0.028) rather than in the males. Besides, we found the higher expression of HYAL1 protein in PTC than that in BTN patients (IHC score: 2.3 vs. 0.5, p=1.00E-06). Our study suggested altered methylation and expression of HYAL1 could be a novel and potential biomarker in distinguishing malignant and benign thyroid nodules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Nanjing Medical University, Nanjing, China.
- Department of Thyroid and Breast Surgery, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, China.
- Department of Pathology, Nantong University Affiliated Hospital, Nantong, China.
- Department of Pathology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, China.
Zitieren
APA
Li, M., Yin, Y., Zhang, M., Jiang, C., Li, H., & Yang, R. (2023). DNA Methylation Status of HYAL1 in Malignant and Benign Thyroid Nodules. Hormone and Metabolic Research, 55(12), 869-875. https://doi.org/10.1055/a-2188-0050
Vancouver
Li M, Yin Y, Zhang M, Jiang C, Li H, Yang R. DNA Methylation Status of HYAL1 in Malignant and Benign Thyroid Nodules. Hormone and Metabolic Research. 2023;55(12):869-875. doi:10.1055/a-2188-0050
BibTeX
@article{Li2023,
author = {Li, Mengxia and Yin, Yifei and Zhang, Minmin and Jiang, Chenxia and Li, Hong and Yang, Rongxi},
title = {DNA Methylation Status of HYAL1 in Malignant and Benign Thyroid Nodules},
journal = {Hormone and Metabolic Research},
year = {2023},
volume = {55},
number = {12},
pages = {869--875},
doi = {10.1055/a-2188-0050}
}
EUVIMED